| Literature DB >> 27062991 |
Rong Zhang1, Dan-xia Gu1, Yong-lu Huang1, Edward Wai-Chi Chan2,3, Gong-Xiang Chen1, Sheng Chen2,3.
Abstract
The origin of pathogenic Enteroaggregative Escherichia coli (EAEC), a major causative agent of childhood diarrhea worldwide, remains ill-defined. The objective of this study was to determine the relative prevalence of EAEC in clinical and non-clinical sources and compare their genetic characteristics in order to identify strains that rarely and commonly cause human diarrhea. The virulence gene astA was commonly detectable in both clinical and non-clinical EAEC, while clinical isolates, but not the non-clinical strains, were consistently found to harbor other virulence factors such as aap (32%), aatA (18%) and aggR (11%). MLST analysis revealed the extremely high diversity of EAEC ST types, which can be grouped into three categories including: (i) non-clinical EAEC that rarely cause human infections; (ii) virulent strains recoverable in diarrhea patients that are also commonly found in the non-clinical sources; (iii) organisms causing human infections but rarely recoverable in the non-clinical setting. In addition, the high resistance in these EAEC isolates in particular resistance to fluoroquinolones and cephalosporins raised a huge concern for clinical EAEC infection control. The data from this study suggests that EAEC strains were diversely distributed in non-clinical and clinical setting and some of the clinical isolates may originate from the non-clinical setting.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27062991 PMCID: PMC4827025 DOI: 10.1038/srep24321
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Distribution of sampling locations and sites where EAEC were recovered in Hangzhou, China.
The figure was generated by obtaining the map of Hanzhou city from Zhejiang Administration of Surveying Mapping and Geoinformation (ZheS(2010)280) with the agency’s permission and further refined by Adobe Photoshop CS2 software.
Detection of virulence genes in 84 EAEC isolates recovered from different sources.
| Sampling Sources (No. of isolates) | No. of EAEC isolates carrying virulence gene (%) | ||||||
|---|---|---|---|---|---|---|---|
| Clinical EAEC isolates (n = 51) | 45 (88) | 5 (10) | 4 (8) | 8 (16) | 1 (2) | 14 (27) | 0 (0) |
| Diarrheal outpatients (n = 30) | 26 (87) | 4 (13) | 1 (3) | 7 (23) | 1 (3) | 10 (33) | 0 (0) |
| Diarrheal children (n = 14) | 12 (86) | 1 (7) | 3 (21) | 1 (7) | 0 (0) | 4 (29) | 0 (0) |
| Non diarrheal inpatients (n = 7) | 7 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Non-clinical EAEC isolates (n = 33) | 30 (91) | 0 (0) | 3 (9) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Healthy human (n = 5) | 3 (60) | 0 (0) | 2 (40) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Companion animals (n = 6) | 5 (83) | 0 (0) | 1 (17) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Swine (n = 15) | 15 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Water (n = 7) | 7 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Total (n = 84) | 75 (89) | 5 (6) | 7 (8) | 8 (10) | 1 (1) | 14 (17) | 0 (0) |
Distribution of phylogenetic subgroups among EAEC isolates from different sampling sources.
| Sampling sources | No. of isolates (%) | |||
|---|---|---|---|---|
| A | B1 | B2 | D | |
| Clinical EAEC isolates (n = 44) | 21 (48) | 6 (14) | 7 (16) | 17 (39) |
| Diarrheal outpatients (n = 30) | 13 (43) | 5 (17) | 3 (10) | 9 (30) |
| Diarrheal children (n = 14) | 5 (36) | 0 (0) | 2 (14) | 7 (50) |
| Non-diarrheal inpatients (n = 7) | 3 (43) | 1 (14) | 2 (29) | 1 (14) |
| Non-clinical EAEC isolates (n = 33) | 8 (24) | 6 (18) | 4 (12) | 15 (46) |
| Healthy human (n = 5) | 2 (40) | 1 (20) | 1 (20) | 1 (20) |
| Companion animals (n = 6) | 1 (17) | 0 (0) | 1 (17) | 4 (67) |
| Swine (n = 15) | 3 (20) | 4 (27) | 2 (13) | 6 (40) |
| Water (n = 7) | 2 (29) | 1 (14) | 0 (0) | 4 (57) |
| Total (n = 84) | 29 (35) | 12 (14) | 11 (13) | 32 (38) |
Distribution of sequence types among 51 clinical and 33 non-clinical/environmental EAEC isolates.
| Sampling sources (no. of isolates) | Sequence Types (no. of isolates) |
|---|---|
| Clinical EAEC isolates (n = 44) | Total of 41 STs |
| Diarrheal outpatients (n = 30) | |
| Diarrheal children (n = 14) | |
| Non-diarrheal inpatients (n = 7) | ST69 (1); |
| Non-clinical EAEC isolates (n = 33) | Total of 30 STs |
| Companion animals (n = 6) | ST12 (1); |
| Healthy human (n = 5) | ST52 (1); ST717 (1); ST767 (1); ST998 (1); ST2253 (1) |
| Swine (n = 15) | ST7 (1); |
| Water (n = 7) |
Sequence types recoverable in both clinical and non-clinical strains are shown in bold fond. For example, ST10 was recovered in both clinical (diarrheal patients) and non-clinical (swine and water) sources. Sequence types present in two or more sub-groups of the clinical or non-clinical strains are underlined. For example, ST38 was found in diarrheal outpatients and diarrheal children from clinical sources; ST746 was identified from swine and water of non-clinical sources.
Figure 2Minimal spanning tree based on multilocus sequence typing of EAEC isolates.
Colored circles represent different sequence types. Black connecting lines indicate single-locus variants; gray connecting lines indicate double-locus variants; dashed connecting lines indicate strains with ≥3 differing loci; and shadowing indicates that >2 sequence types belong to one clonal complex.
Antimicrobial susceptibility of 84 EAEC strains isolated of different origins.
| Sampling sources | Resistance rate (%) | CTX-M variants (No. of isolates) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CIP | LEV | CTX | CAZ | CXM | GEN | AMK | AMP | IPM | MEM | ||
| Clinical EAEC isolates (51) | 30 | 30 | 50 | 14 | 55 | 27 | 5 | 84 | 0 | 0 | M-14, 15, 24, 55, 65 |
| Diarrheal outpatients (n = 30) | 30 | 30 | 40 | 10 | 47 | 17 | 3 | 83 | 0 | 0 | M-14 (10), M-55 (2) |
| Diarrheal children (n = 14) | 29 | 29 | 71 | 21 | 71 | 50 | 7 | 85 | 0 | 0 | M-14 (5), M-55 (1), M-65 (1), M-24 (1), M-15 (1) |
| Non-diarrheal inpatients (n = 7) | 43 | 43 | 57 | 43 | 57 | 0 | 0 | 86 | 29 | 29 | M-14 (1), M-55 (1), M-3 (1), NDM-1(2) |
| Non-clinical EAEC isolates (33) | 53 | 53 | 53 | 9 | 53 | 43 | 7 | 87 | 0 | 0 | M-14, 24, 55, 64, 65 |
| Healthy human (n = 5) | 20 | 20 | 20 | 0 | 20 | 20 | 0 | 40 | 0 | 0 | M-14 (1), M-55 (1) |
| Companion animals (n = 6) | 67 | 67 | 67 | 50 | 50 | 50 | 0 | 67 | 0 | 0 | M-24 (1), M-64(1), M-65 (1) |
| Swine (n = 15) | 60 | 60 | 60 | 0 | 60 | 27 | 7 | 93 | 0 | 0 | M-14(6), M-24 (1), M-64(1), M-65 (1) |
| Water (n = 7) | 29 | 29 | 29 | 29 | 43 | 57 | 14 | 86 | 0 | 0 | M-14 (1) |
CIP, ciprofloxacin; LEV, levofloxacin; CTX, cefotaxime; CAZ, ceftazidime; CXM, cefuroxime; GEN, gentamycin; AMK, amikacin; AMP, ampicillin; IPM, imipenem; MEM, meropenem.